Advertisement

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam and Kensei Tobinai

Article Information

Citation 
vol. 133 no. 2 137-146
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted April 27, 2018
  • Accepted October 2, 2018
  • Published online January 10, 2019.

Article Versions


Contributors 
  • Shigeru Kusumoto, 1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;
  • Luca Arcaini, 2Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 3Department of Molecular Medicine, University of Pavia, Pavia, Italy;
  • Xiaonan Hong, 4Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;
  • Jie Jin, 5Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;
  • Won Seog Kim, 6Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
  • Yok Lam Kwong, 7Department of Medicine, Queen Mary Hospital, Hong Kong, China;
  • Marion G. Peters, 8Department of Medicine, University of California, San Francisco, San Francisco, CA;
  • Yasuhito Tanaka, 9Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;
  • Andrew D. Zelenetz, 10Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY; 11Department of Medicine, Weill Cornell Medical Center, New York, NY;
  • Hiroshi Kuriki, 12Clinical Science & Strategy Department, Oncology Clinical Science & Strategy, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan;
  • Günter Fingerle-Rowson, 13Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and
  • Tina Nielsen, 13Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and
  • Eisuke Ueda, 12Clinical Science & Strategy Department, Oncology Clinical Science & Strategy, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan;
  • Hanna Piper-Lepoutre, 13Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and
  • Gila Sellam, 13Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and
  • Kensei Tobinai, 14Department of Hematology, National Cancer Center Hospital, Tokyo, Japan

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output